Glucomannan noodle
Dietary SupplementThe participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
NCT Number: NCT02711306
Metabolic syndrome (MS) is a complex disease with a cluster of risk factors and clinical features, which includes central or abdominal obesity, atherogenic dyslipidemia, impaired glucose regulation, hyperinsulinemia, high blood pressure, and concomitance of pro-inflammatory cytokine and insulin resistance. Glucomannan (GM) is a water-soluble dietary fiber derived from the root of Amorphophallus konjac that can improve blood sugar, blood fat concentration, and weight management, and has other health benefits.The purposes of this study are going to investigate the effects of KGM noodle (KGN) as stable food to MS and diabetic patients.
Looking for future studies?
Notify Me20 year–64 year
All sexes
Interventional
Not applicable
The KGN diet was composed of well-cooked noodle with 2 g of KGM in a dosage of 200 g/piece twice daily to substitute the daily carbohydrate for 4 weeks, with a 2-week washout period between alternative diets. All 33 subjects received two servings of either GMNs or PNs (400 g) per day, which replaced the main carbohydrate in two daily meals for 4 weeks. After a 2-week washout period, the subjects received the other type of noodle for 4 weeks. The body weight, BMI, waist circumference, fasting blood glucose and lipid profile, as well as serum vitamin A, E, β-carotene and high sensitivity C-reactive protein (hs-CPR) were measured by HPCL.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Adults with metabolic syndrome
Subjects were considered to have metabolic syndrome if subjects had 3 of the following 5 characteristics:
Exclusion criteria
The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
Time frame: 4 weeks
Body weight by weighting scale (kilogram). Lower scores mean a better outcome in subjects.
Time frame: 4 weeks
Body waist by tape in centimeter
Time frame: 4 weeks
HbA1c (glycated hemoglobin) analysis
Time frame: 4 weeks
LDL-C (low density lipoprotein cholesterol) analysis
Taipei Medical University
Other
Office of Human Research, Taipei Medical University
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05956886
Dyssomnias, Glucose Metabolism Disorders
Newark, Delaware, United States
View Trial DetailsNCT07739602
Glucose Metabolism Disorders, Hyperinsulinism
Wroclaw, Poland
View Trial DetailsNCT04057339
Behavior, Fasting
La Jolla, California, United States
View Trial DetailsNCT07702669
Glucose Metabolism Disorders, Hyperinsulinism
Harbin, Heilongjiang, China
View Trial Details